Martin DS - Search Results

1

Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.

Kemeny NE, Schneider A, Martin DS. Kemeny NE, et al. Among authors: martin ds. Cancer Invest. 1990;8(2):263-4. doi: 10.3109/07357909009017578. Cancer Invest. 1990. PMID: 2400946 No abstract available.

2

Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.

Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W. Kemeny N, et al. J Clin Oncol. 1992 May;10(5):747-52. doi: 10.1200/JCO.1992.10.5.747. J Clin Oncol. 1992. PMID: 1569447

3

A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA).

Kemeny N, Seiter K, Martin D, Urmacher C, Niedzwiecki D, Kurtz RC, Costa P, Murray M. Kemeny N, et al. Ann Intern Med. 1991 Dec 15;115(12):946-51. doi: 10.7326/0003-4819-115-12-946. Ann Intern Med. 1991. PMID: 1824554 Clinical Trial.

4

Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.

Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R. Seiter K, et al. Cancer. 1993 Mar 1;71(5):1875-81. doi: 10.1002/1097-0142(19930301)71:5<1875::aid-cncr2820710526>3.0.co;2-9. Cancer. 1993. PMID: 8448752

5

Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.

Martin DS, Kemeny NE. Martin DS, et al. Semin Oncol. 1992 Apr;19(2 Suppl 3):228-33. Semin Oncol. 1992. PMID: 1557654 Review.

6

Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.

Martin DS, Kemeny NE. Martin DS, et al. Semin Oncol. 1992 Apr;19(2 Suppl 3):49-55. Semin Oncol. 1992. PMID: 1557657 Review.

7

Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.

Kemeny N, Schneider A, Martin DS, Colofiore J, Sawyer RC, Derby S, Salvia B. Kemeny N, et al. Among authors: martin ds. Cancer Res. 1989 Aug 15;49(16):4636-9. Cancer Res. 1989. PMID: 2472883

8

Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.

Casper ES, Michaelson RA, Kemeny N, Martin DS, Young CW. Casper ES, et al. Among authors: martin ds. Cancer Treat Rep. 1984 Mar;68(3):539-41. Cancer Treat Rep. 1984. PMID: 6704982

9

Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.

Woodcock TM, Martin DS, Damin LA, Kemeny NE, Young CW. Woodcock TM, et al. Among authors: martin ds. Cancer. 1980 Mar 15;45(5 Suppl):1135-43. doi: 10.1002/1097-0142(19800315)45:5+<1135::aid-cncr2820451318>3.0.co;2-q. Cancer. 1980. PMID: 7357508

10

Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.

Lynch G, Kemeny N, Chun H, Martin D, Young C. Lynch G, et al. Cancer Treat Rep. 1985 Feb;69(2):179-84. Cancer Treat Rep. 1985. PMID: 3971391

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

490 results

Search Page

Filters